Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dosing of Zoledronic Acid in CTIBL
NCT00712985Phase 3Completed
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2005
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in Cancer Treatment-Induced Bone Loss (CTIBL), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Number of Participants With Urine and Serum NTx and Serum CTx Within Normal Range at 12 months. Started Sep 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
Cancer Treatment-Induced Bone Loss (CTIBL)
Beyond the preview
Go deeper on NCT00712985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00712985.